Trademark Overview
On Wednesday, November 6, 2024, a trademark application was filed for CANCILICO with the United States Patent and Trademark Office. The USPTO has given the CANCILICO trademark a serial number of 79413341. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Monday, September 15, 2025. This trademark is owned by Cancilico GmbH. The CANCILICO trademark is filed in the Computer & Software Products & Electrical & Scientific Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Computer software platforms, recorded or downloadable for the processing and displaying of medical images; cloud-based or locally deployed artificial intelligence software for healthcare for medical image analysis; downloadable and non-downloadable interactive software based on artificial intelligence for the analysis of medical images; downloadable and non-downloadable artificial intelligence software for analysis of scientific data; downloadable and non-downloadable databases in the fields of hematology and oncology; data storage programs, namely, for cloud-based storage of scientific or medical data; non-downloadable interactive databases in the field of medical images in hematology and oncology; downloadable and non-downloadable interactive database software for database management; downloadable and non-downloadable computer programmes for data processing; real-time data processing apparatus; electric digital sensors; digital measuring apparatus, namely, digital microscopy or slide...
Conducting of medical bone marrow analysis for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; medical diagnostic services; providing medical diagnostic services, by means of artificial intelligence; conducting of medical cell detection and analysis for the diagnosis of cancer.
Scientific research for medical purposes in the area of cancerous diseases; scientific development of automated cell detection processes, by means of artificial intelligence; scientific development of digital biomarkers for diagnostics and therapy control in the fields of oncology and hematology; development of artificial intelligence systems, for use in the field of cancer diagnostics; platforms for artificial intelligence as software as a service (SAAS), namely, software as a service (SAAS) services featuring software for analyzing and reporting scientific research information; providing artificial intelligence computer programs on data networks, namely, providing temporary use of online non-downloadable software for analysis and reporting of scientific data via the global computer network; online data storage, for use in the field of cancer diagnostics; clinical research in the fields of hematology, pathology and oncology; scientific research in the nature of conducting clinical tri...
